Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta‐Analysis
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Aims: To compare the efficacy and safety of different hybrid closed loop (HCL) systems in people with diabetes through a network meta‐analysis. Methods: We searched MEDLINE, EMBASE, CENTRAL and PubMed for randomised clinical trials (RCTs) enrolling children, adolescents and/or adults with type 1 or type 2 diabetes, evaluating Minimed 670G, Minimed 780G, Control‐IQ, CamAPS Fx, DBLG‐1, DBLHU, and Omnipod 5 HCL systems against other types of insulin therapy, and reporting time in target range (TIR) as outcome. Results: A total of 28 RCTs, all enrolling people with type 1 diabetes, were included. HCL systems significantly increased TIR compared with subcutaneous insulin therapy without continuous glucose monitoring (SIT). Minimed 780G achieved the highest TIR ahead of Control IQ (mean difference (MD) 5.1%, 95% confidence interval (95% CI) [0.68; 9.52], low certainty), Minimed 670G (MD 7.48%, 95% CI [4.27; 10.7], moderate certainty), CamAPS Fx (MD 8.94%, 95% CI [4.35; 13.54], low certainty), and DBLG1 (MD 10.69%, 95% CI [5.73; 15.65], low certainty). All HCL systems decreased time below target range, with DBLG1 (MD −3.69%, 95% CI [−5.2; −2.19], high certainty), Minimed 670G (MD −2.9%, 95% CI [−3.77; −2.04], moderate certainty) and Minimed 780G (MD −2.79%, 95% CI [−3.94; −1.64], high certainty) exhibiting the largest reductions compared to SIT. The risk of severe hypoglycaemia and diabetic ketoacidosis was similar to other types of insulin therapy. Conclusions: We show a hierarchy of efficacy among the different HCL systems in people with type 1 diabetes, thus providing support to clinical decision‐making. Trial Registration: PROSPERO CRD42023453717
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 2×
“If the mean was missing, it was calculated by dividing the sum of the median, first quartile, and third quartile by 3 [13].”
InfluentialChecking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“Local consistency in networks was evaluated by comparing direct with indirect evidence [16] and global consistency with the design‐ by‐treatment interaction model [17].”
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098 · cited 1×
“Local consistency in networks was evaluated by comparing direct with indirect evidence [16] and global consistency with the design‐ by‐treatment interaction model [17].”
CINeMA: an approach for assessing confidence in the results of a network meta-analysis
Nikolakopoulou, A., Higgins, J. P. T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., & Salanti, G. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003082 · Cited by 1,935 · cited 1×
“We assessed confidence in network meta‐analysis estimates using the CINeMA (Confidence In Network Meta‐Analysis) framework and online application [20].”
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831 · cited 2×
“Firstly, since the included studies used different brands of sensors, comparisons of CGM outcomes should be interpreted with caution [24].”
netmeta : An R Package for Network Meta-Analysis Using Frequentist Methods
Balduzzi, S., Rücker, G., Nikolakopoulou, A., Papakonstantinou, T., Salanti, G., Efthimiou, O., & Schwarzer, G. (2023) · Journal of Statistical Software · doi:10.18637/jss.v106.i02 · Cited by 532
Network meta-analysis: application and practice using R software
Shim, S. R., Kim, S.-J., Lee, J., & Rücker, G. (2019) · Epidemiology and Health · doi:10.4178/epih.e2019013 · Cited by 483 · cited 1×
“We performed random‐effects frequentist network meta‐ analyses [14], using MD and 95% CI for TIR, TBR, TBR 54 mg/dL, TAR, 24‐h mean sensor glucose and CV, and odds ratio (OR) and 95% CI for the risk of severe hypoglycaemic events and diabetic ketoacidosis.”
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443 · cited 2×
“Given the pre-liminary indications of efficacy and safety in this population, a consensus of experts recommends considering the initiation of appropriate HCL systems in patients with type 2 diabetes [23].”
Bekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Maiorino, M. I., Signoriello, S., Maio, A., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2020) · Diabetes Care · doi:10.2337/dc19-1459 · Cited by 364
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250 · cited 1×
“%) with no change in level 1 hypoglycaemia and with a statistically significant, although overall minimal, increase in level 2 hypoglycaemia [35, 36].”
Automated insulin delivery in women with pregnancy complicated by type 1 diabetes
Lee, T. T. M., Collett, C., Bergford, S., Hartnell, S., Scott, E. M., Lindsay, R. S., Hunt, K. F., McCance, D. R., Barnard-Kelly, K., Rankin, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303911 · Cited by 241
Multicenter, randomized trial of a bionic pancreas in type 1 diabetes
Bionic Pancreas Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2205225 · Cited by 216
Choudhary, P., Kolassa, R., Keuthage, W., Kroeger, J., Thivolet, C., Evans, M., Ré, R., de Portu, S., Vorrink, L., Shin, J., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00212-1 · Cited by 204 · cited 1×
“HCL systems have been shown to reduce HbA1c levels and increase time spent within target glucose range (TIR) without increasing time spent below range (TBR) and hypoglycaemic events, and in some studies to reduce hypoglycaemia [8–10].”
Charleer, S., Mathieu, C., Nobels, F., De Block, C., Radermecker, R. P., Hermans, M. P., Taes, Y., Vercammen, C., T'Sjoen, G., Crenier, L., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02498 · Cited by 196
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems
Peacock, S., Frizelle, I., & Hussain, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01394-5 · Cited by 122
Dicembrini, I., Cosentino, C., Monami, M., Mannucci, E., & Pala, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01589-3 · Cited by 106
Castellana, M., Parisi, C., Di Molfetta, S., Di Gioia, L., Natalicchio, A., Perrini, S., Cignarelli, A., Laviola, L., & Giorgino, F. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001092 · Cited by 84
Self-citationUhl, S., Choure, A., Rouse, B., Loblack, A., & Reaven, P. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad652 · Cited by 76
Forlenza, G. P., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., McGill, J. B., Umpierrez, G., & Aleppo, G. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0206 · Cited by 70
Levy, C. J., Raghinaru, D., Kudva, Y. C., Pandit, K., Blevins, T., Casaubon, L., Desjardins, D., Levister, C. M., O’Malley, G., Reid, C., et al. (2024) · Clinical Diabetes · doi:10.2337/cd23-0025 · Cited by 37 · cited 1×
“More recently, in a 6‐week prospective single arm trial [37], 30 adults with type 2 diabetes using the Control‐IQ system achieved substantial glycaemic improvement (increase in TIR by 15% and reduction in mean glucose by 22 mg/dL) with no increase in hypoglycaemia.”
Tornese, G., Carletti, C., Lanzetta, M. A., Tamaro, G., Barbi, E., & Faleschini, E. (2023) · Diabetes Care · doi:10.2337/dc22-2046 · Cited by 29 · cited 1×
“The reassuring safety profile of commercial HCL systems is supported by ever‐growing observations from the real world [27, 28].”
Cited by
Alfadli, S. F., Alotaibi, Y. S., Aqdi, M. J., Almozan, L. A., Alzubaidi, Z. B., Altemani, H. A., Almutairi, S. D., Alabdullah, H. A., Almehmadi, A. A., Alanzi, A. L., et al. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100382 · Cited by 16
Tumminia, A., Santoro, G. M., Oteri, V., Galeano, F., Baratta, R., Gullo, D., Frittitta, L., Sciacca, L., Moli, R. L., Piticchio, T., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112173 · Cited by 9
Nieto de la Marca, M. D. L. O., Fernández Velasco, P., Del Amo Simón, S., Sánchez Ibáñez, M., Collantes Matallana, A., Gómez Hoyos, E., Torres Torres, B., Ortolá Buigues, A., de Luis Román, D. A., & Díaz Soto, G. (2026) · Endocrine · doi:10.1007/s12020-026-04743-z
Metadata
- Authors
- Di Molfetta, S., Di Gioia, L., Caruso, I., Cignarelli, A., Green, S. C., Natale, P., Strippoli, G. F. M., Sorice, G. P., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2024-09
- Volume
- 40
- Issue
- 6
- Pages
- e3842-e3842
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W4402639355
- Cited by
- 76
- References
- 23
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.